No Clinically Significant Interaction Between Lamotrigine and Amiodarone
Based on available evidence, lamotrigine and amiodarone do not have a clinically significant pharmacokinetic or pharmacodynamic interaction that requires dose adjustment or avoidance of concurrent use.
Key Evidence Analysis
The FDA labeling for lamotrigine 11 provides comprehensive guidance on drug interactions, specifically identifying medications that affect lamotrigine metabolism through glucuronidation pathways. Amiodarone is notably absent from this list. The label specifically mentions:
- Glucuronidation inducers requiring dose adjustments: carbamazepine, phenytoin, phenobarbital, primidone, rifampin, and protease inhibitors (lopinavir/ritonavir, atazanavir/ritonavir)
- Estrogen-containing contraceptives that increase lamotrigine clearance up to 2-fold
- Valproate which inhibits lamotrigine metabolism
Similarly, amiodarone guidelines 22 detail its major drug interactions through CYP450 inhibition (CYP 2C9, CYP 2D6, CYP 3A4) and P-glycoprotein inhibition. The clinically important interactions highlighted are:
- Warfarin (requires INR monitoring weekly for 6 weeks)
- Digoxin (levels predictably double; reduce dose by 50%)
- Beta blockers, calcium channel blockers, cyclosporine
Lamotrigine is not metabolized by the CYP450 pathways that amiodarone inhibits - it undergoes glucuronidation, not CYP metabolism.
Pharmacodynamic Considerations
Research evidence 3 demonstrates that both lamotrigine and amiodarone affect sodium channels, but with different clinical implications:
- Lamotrigine impaired peripheral chemoreceptor responses to hypoxia in experimental models
- Amiodarone did not affect chemoreceptor function or ventilatory responses at therapeutic doses
More importantly, a large retrospective cohort study 4 of 11,786 lamotrigine users (mean age 77.6 years) found no increased risk of ventricular arrhythmia or sudden cardiac arrest compared to levetiracetam users (HR 0.84,95% CI 0.67-1.06). Among patients with baseline arrhythmias or using antiarrhythmic drugs, lamotrigine actually showed reduced risk (HR 0.51 and 0.67 respectively).
Clinical Bottom Line
You can safely prescribe lamotrigine and amiodarone together without dose adjustments. No special monitoring beyond standard protocols for each individual medication is required. The 2020 FDA safety warning on lamotrigine regarding cardiac effects 4 was not supported by subsequent large-scale evidence and does not contraindicate use with amiodarone.
Standard Monitoring Remains Appropriate:
- For amiodarone: thyroid function, liver enzymes, pulmonary function every 6 months; heart rate surveillance during loading 22
- For lamotrigine: clinical response and adverse effects per standard epilepsy/psychiatric care
Important Caveat:
While experimental data 5 showed amiodarone enhanced anticonvulsant effects of some antiepileptic drugs in mice, this has not translated to clinically significant interactions requiring dose modification in humans. Brain concentrations of lamotrigine were not affected by amiodarone in these studies.